Compare Incyte Corporation (INCY) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Victoria's Secret & Co — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while Victoria's Secret & Co trades at $87.05 (market cap $6.95B). The key difference: Incyte Corporation is far larger — about 3.3× Victoria's Secret & Co's market cap. Which is the better fit depends on your goals.
| INCY | VSXY | |
|---|---|---|
Market Cap | $23.11B | $6.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $88.50 |
52-Week Low | $67.38 | $18.72 |
Enterprise Value | $19.13B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Victoria's Secret (VSXY) trades at $87.49, up 7.42% today, with a bullish technical signal and strong momentum. Recent earnings beats in Q3 2025, Q4 2025, and Q1 2026 highlight improving fundamentals, while international growth and product innovation drive positive sentiment. The stock is near its consensus price target of $88.56, with net cash flow turning positive in 2026 projections.
Outlook remains favorable with analyst consensus at Buy (55.56% of coverage), though valuation multiples like P/E of 32.45 and net margin of 3.12% suggest premium pricing. Risks include competitive pressures and reliance on international expansion, but institutional support and earnings momentum support upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
